Lateral elbow tendinopathy · Randomized trial · 2024
How did radial shockwave compare with exercise or advice for tennis elbow?
In this small trial of 60 people with tennis elbow, all three groups improved. After three radial shockwave sessions, the elbow pain-and-function score fell from about 44 to about 18 out of 100 by 3 months. The exercise and advice groups also improved, to about 26 and 24.
Improved over time in all groups- adults with tennis elbow
- 60
- shockwave sessions, about a week apart
- 3
- months of follow-up
- 6
Good to know: A small pilot trial to plan a larger study. Everyone attended all their shockwave sessions.
Sveinall H, Brox JI, Engebretsen KB, et al. BMJ Open, 2024 · Read the paper ↗
How this study worked
Conceptual animation: a radial wave spreads from the applicator and weakens with distance. Not to scale. Tap the field to send a pulse.
What happened
Tennis elbow pain and function
PRTEE score, 0–100 · lower means fewer symptoms
Shockwave + adviceExercise + adviceAdvice alone
Show the numbers
| Group | Start | 3 months | 6 months |
|---|---|---|---|
| Shockwave + advice | 43.8 | 18.1 | 15.3 |
| Exercise + advice | 43 | 25.7 | 20.5 |
| Advice alone | 48.6 | 23.9 | 13.7 |
The treatment
Shockwave + advice
Radial, once a week for 3 weeks
- Sessions
- 3, one a week
- Pulses
- 2,000 per session
- Strength
- 1.5–3bar · 10 per second
- Numbing
- Not mentioned
- Device
- EMS-DolorClast, Swiss DolorClast Evo blue handpiece
- Everyone also got
- Information and advice on gradually loading the arm
Compared with: Heavy slow resistance exercise at home for 12 weeks, or information and advice alone
Settings are what each study used, not a prescription.
Who took part
60 adults (average age about 48, 68% women) with tennis elbow in Norwegian hospital care, 20 in each group.
Side effects
Two people had more pain for up to 12 hours after shockwave. In the exercise group, five reported more pain from training.
All the numbers and the full appraisal
Every reported result
The results, in numbers.
60 adults with tennis elbow randomized 20 per arm in Norwegian secondary care; mean age 47.8 (SD 9.3), 68% women. Feasibility sample, not effectiveness cohort.
Twenty randomized per arm. Follow-up completion varied; arm-specific analyzed denominator is stated per outcome when reported.
Twenty randomized per arm. Follow-up completion varied; arm-specific analyzed denominator is stated per outcome when reported.
Twenty randomized per arm. Follow-up completion varied; arm-specific analyzed denominator is stated per outcome when reported.
Trial feasibility and progression criteria1 reported outcome
Trial feasibility and progression criteria
Counts, percentages and prespecified process thresholds
Eligibility (78%), willingness to be randomised (92%) and ESWT attendance (100%) met their targets, but the recruitment rate (3.37 per month) was below the 3.75 target; 6-month retention was 68%, below the >75% criterion. Training compliance was low: 6/19 (32%) achieved at least 30 of 36 sessions. Authors conclude amendments are needed before a full trial.
Analysis details and source
Table 2 exact feasibility results: eligible for randomization 69/89 (78%); willing 60/65 (92%); recruitment 3.37/month; training attendance 38/42 (90%); ESWT attendance 60/60 (100%); ≥30/36 training sessions 6/19 (32%). Acceptability baseline: advice 16/20 (80%), training 19/20 (95%), ESWT 20/20 (100%); at 3 months: 11/18 (61%), 13/19 (68%), 20/20 (100%). Understandability baseline: 18/20 (90%), 20/20 (100%), 20/20 (100%); at 3 months: 14/18 (78%), 18/19 (95%), 20/20 (100%). Retention 58/60 (97%) at 3 months and 41/60 (68%) at 6 months. Data completeness: baseline PRTEE, Quick-DASH, EQ-5D-5L and grip 60/60 each; 3 months 57/58, 58/58, 58/58, 58/58; 6 months PRTEE, Quick-DASH and EQ-5D each 41/41. Table 2 has no 6-month grip entry. These process outcomes are descriptive, not efficacy comparisons.
Patient-Rated Tennis Elbow Evaluation total score1 reported outcome
Patient-Rated Tennis Elbow Evaluation total score
Patient-Rated Tennis Elbow Evaluation (PRTEE) PRTEE points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Radial ESWT | — | 43.8 (SD 13.9) | 18.1 (SD 17.5) |
| Heavy-slow resistance training | — | 43 (SD 19) | 25.7 (SD 25.2) |
| Information and advice | — | 48.6 (SD 18.2) | 23.9 (SD 19.7) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
Descriptive mean scores decreased in all groups. This feasibility trial was not designed to compare treatment effectiveness.
Analysis details and source
Table 4 baseline and 3-month group means (SD); the 6-month means are separately structured. Arm-specific analyzed n is not stated. Descriptive feasibility data only; not an efficacy comparison.
PRTEE pain subscale2 reported outcomes
PRTEE pain subscale
Patient-Rated Tennis Elbow Evaluation pain PRTEE points (0–50)
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Radial ESWT | — | 24.8 (SD 7.6) | 11.4 (SD 9.6) |
| Heavy-slow resistance training | — | 24.6 (SD 10.4) | 15.9 (SD 14.3) |
| Information and advice | — | 25.2 (SD 9.5) | 14.2 (SD 10.2) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
Descriptive group summaries in a feasibility trial; no comparative effectiveness inference.
Analysis details and source
Table 4 baseline and 3-month group means (SD); the 6-month means are stored separately in the matching 6-month outcome. Table 4 reports no change scores. Arm-specific n is not supplied for these summary rows; no n has been inferred.
PRTEE pain subscale at 6 months
Patient-Rated Tennis Elbow Evaluation pain PRTEE points (0–50)
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Radial ESWT | — | — | 9.2 (SD 8.8) |
| Heavy-slow resistance training | — | — | 11.9 (SD 11.3) |
| Information and advice | — | — | 8.7 (SD 5.1) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
Descriptive 6-month group means (SD) in a feasibility trial; no comparative effectiveness inference.
Analysis details and source
Arm-specific analyzed n is not stated in this Table 4 row; no n inferred.
PRTEE function subscale2 reported outcomes
PRTEE function subscale
Patient-Rated Tennis Elbow Evaluation function PRTEE points (0–50)
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Radial ESWT | — | 19 (SD 7.8) | 6.8 (SD 8.1) |
| Heavy-slow resistance training | — | 18.4 (SD 10.1) | 9.8 (SD 12) |
| Information and advice | — | 23.4 (SD 9.8) | 10.3 (SD 10) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
Descriptive group summaries in a feasibility trial; no comparative effectiveness inference.
Analysis details and source
Table 4 baseline and 3-month group means (SD); the 6-month means are stored separately in the matching 6-month outcome. Table 4 reports no change scores. Arm-specific n is not supplied for these summary rows; no n has been inferred.
PRTEE function subscale at 6 months
Patient-Rated Tennis Elbow Evaluation function PRTEE points (0–50)
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Radial ESWT | — | — | 6.1 (SD 7.4) |
| Heavy-slow resistance training | — | — | 8.5 (SD 9.1) |
| Information and advice | — | — | 5 (SD 3.6) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
Descriptive 6-month group means (SD) in a feasibility trial; no comparative effectiveness inference.
Analysis details and source
Arm-specific analyzed n is not stated in this Table 4 row; no n inferred.
Quick-DASH2 reported outcomes
Quick-DASH
Quick Disabilities of the Arm, Shoulder and Hand points (0–100)
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Radial ESWT | — | 42 (SD 10.4) | 17.5 (SD 17.3) |
| Heavy-slow resistance training | — | 41.1 (SD 18) | 27.5 (SD 26.7) |
| Information and advice | — | 46.8 (SD 21.4) | 26.9 (SD 21.2) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
Descriptive group summaries in a feasibility trial; no comparative effectiveness inference.
Analysis details and source
Table 4 baseline and 3-month group means (SD); the 6-month means are stored separately in the matching 6-month outcome. Table 4 reports no change scores. Arm-specific n is not supplied for these summary rows; no n has been inferred.
Quick-DASH at 6 months
Quick Disabilities of the Arm, Shoulder and Hand points (0–100)
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Radial ESWT | — | — | 18 (SD 15.1) |
| Heavy-slow resistance training | — | — | 24.2 (SD 22.2) |
| Information and advice | — | — | 15.7 (SD 8.3) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
Descriptive 6-month group means (SD) in a feasibility trial; no comparative effectiveness inference.
Analysis details and source
Arm-specific analyzed n is not stated in this Table 4 row; no n inferred.
EQ-5D-5L index2 reported outcomes
EQ-5D-5L index
EQ-5D-5L index index units (−0.59 to 1)
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Radial ESWT | — | 0.62 (SD 0.136) | 0.73 (SD 0.269) |
| Heavy-slow resistance training | — | 0.597 (SD 0.179) | 0.674 (SD 0.27) |
| Information and advice | — | 0.551 (SD 0.197) | 0.761 (SD 0.118) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
Descriptive group summaries in a feasibility trial; no comparative effectiveness inference.
Analysis details and source
Table 4 baseline and 3-month group means (SD); the 6-month means are stored separately in the matching 6-month outcome. Table 4 reports no change scores. Arm-specific n is not supplied for these summary rows; no n has been inferred.
EQ-5D-5L index at 6 months
EQ-5D-5L index index units (−0.59 to 1)
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Radial ESWT | — | — | 0.771 (SD 0.161) |
| Heavy-slow resistance training | — | — | 0.733 (SD 0.232) |
| Information and advice | — | — | 0.8 (SD 0.099) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
Descriptive 6-month group means (SD) in a feasibility trial; no comparative effectiveness inference.
Analysis details and source
Arm-specific analyzed n is not stated in this Table 4 row; no n inferred.
Pain-free grip strength1 reported outcome
Pain-free grip strength
Pain-free grip strength kg
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Radial ESWT | — | 20.2 (SD 9.4) | 31.7 (SD 9.7) |
| Heavy-slow resistance training | — | 23.3 (SD 13.7) | 31.9 (SD 15.1) |
| Information and advice | — | 16.6 (SD 8.7) | 24.8 (SD 10.8) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
Descriptive group summaries in a feasibility trial; no comparative effectiveness inference.
Analysis details and source
Table 4 values are means (SD) for baseline and 3 months. Arm-specific n is not supplied for these summary rows; no n has been inferred.
Pain on gripping1 reported outcome
Pain on gripping
Pain on gripping NRS points (0–10)
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Radial ESWT | — | 4 (IQR 1–8) | 0 (IQR 0–4) |
| Heavy-slow resistance training | — | 5 (IQR 2–8) | 0 (IQR 0–7) |
| Information and advice | — | 6 (IQR 4–8) | 2 (IQR 1–6) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
Descriptive group summaries in a feasibility trial; no comparative effectiveness inference.
Analysis details and source
Table 4 values are medians (IQR) for baseline and 3 months. Arm-specific n is not supplied for these summary rows; no n has been inferred.
Current pain NRS-P1 reported outcome
Current pain NRS-P
Numeric rating scale for pain now NRS points (0–10)
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Radial ESWT | — | 5 (IQR 3–7) | 1 (IQR 1–4) |
| Heavy-slow resistance training | — | 5 (IQR 3–7) | 2 (IQR 0–6) |
| Information and advice | — | 5 (IQR 2–7) | 2 (IQR 1–4) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
Descriptive group summaries in a feasibility trial; no comparative effectiveness inference.
Analysis details and source
Table 4 values are medians (IQR) for baseline and 3 months. Arm-specific n is not supplied for these summary rows; no n has been inferred.
GROC success at 3 months3 reported outcomes
GROC success at 3 months
Global Rating of Change (GROC; −6 to +6) participants, n/N (%)
Descriptive feasibility-trial responses; categories are reported as printed and are not efficacy contrasts.
Analysis details and source
Table 4 totals: success 18/58 (31%), improved 38/58 (66%), worse 6/58 (10%). Categories as reported may overlap; arm denominators vary.
GROC improved at 3 months
Global Rating of Change (GROC; −6 to +6) participants, n/N (%)
Descriptive feasibility-trial responses; categories are reported as printed and are not efficacy contrasts.
Analysis details and source
Table 4 totals: success 18/58 (31%), improved 38/58 (66%), worse 6/58 (10%). Categories as reported may overlap; arm denominators vary.
GROC worse at 3 months
Global Rating of Change (GROC; −6 to +6) participants, n/N (%)
Descriptive feasibility-trial responses; categories are reported as printed and are not efficacy contrasts.
Analysis details and source
Table 4 totals: success 18/58 (31%), improved 38/58 (66%), worse 6/58 (10%). Categories as reported may overlap; arm denominators vary.
PRTEE total score at 6 months1 reported outcome
PRTEE total score at 6 months
Patient-Rated Tennis Elbow Evaluation total PRTEE points (0–100)
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Radial ESWT | — | — | 15.3 (SD 15.9) |
| Heavy-slow resistance training | — | — | 20.5 (SD 20.3) |
| Information and advice | — | — | 13.7 (SD 8.6) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
Descriptive 6-month group means (SD) in a feasibility trial; no comparative effectiveness inference.
Analysis details and source
Arm-specific analyzed n is not stated in this Table 4 row; no n inferred.
How treatment was delivered
EMS-DolorClast with Swiss DolorClast Evo blue handpiece and 15-mm applicator.
Three sessions about one week apart; 2,000 impulses at 10 Hz; low energy 1.5–3 bar; maximal tenderness at lateral epicondyle. No conversion from bar.
12 weeks, 36 home sessions, two dumbbell exercises; three sets; 4 s concentric and 4 s eccentric; three times weekly, at least 48 h recovery; load as heavy as possible within repetitions.
All groups received oral and written information, reassurance that pain does not equal harm, and gradual load management advice.
Exercise group: five participants reported increased pain from training as an adverse event; eight cited pain aggravation as a reason for non-compliance. ESWT group: two reported increased pain for up to 12 hours. No serious-event summary/count is clearly reported in the inspected source.
The authors note that 6-month retention was 68%, below the >75% criterion, and postal questionnaires may explain some loss.
Amber progression cutoffs were not set a priori; authors suggest feasibility success criteria may have been too permissive.
No blinded assessor; acceptability was reported to the treating physiotherapist, risking observer/reporting bias.
Secondary symptoms are descriptive in a feasibility study and should not be treated as efficacy comparisons.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- The authors note that 6-month retention was 68%, below the >75% criterion, and postal questionnaires may explain some loss.
- Amber progression cutoffs were not set a priori; authors suggest feasibility success criteria may have been too permissive.
- No blinded assessor; acceptability was reported to the treating physiotherapist, risking observer/reporting bias.
- Secondary symptoms are descriptive in a feasibility study and should not be treated as efficacy comparisons.
Source-linked critical reading
Randomized feasibility trial
Technical source record
All article sections, Tables 1–4 and footnotes, figure captions, Results, Discussion, limitations and disclosure/data statements read. Raw XML contains four table-wraps matching parsed tables. Reviewer comments PDF referenced by the source was unavailable.
Most participants attended all three shockwave sessions, but this study was designed to test whether a larger trial can be done, not which treatment works best. Pain increased temporarily for some participants. The symptom scores should not be taken as proof that shockwaves are more effective.
Is a three-arm trial of heavy-slow resistance exercise, radial ESWT or information and advice feasible for tennis elbow in Norwegian secondary care, and what descriptive symptom changes occur?
Single-centre, three-arm, 1:1:1 randomized feasibility trial with follow-up at 3 and 6 months. A feasibility study, not an effectiveness trial; symptom outcomes are descriptive.
60 adults with tennis elbow were randomized, 20 per group. Mean age was 47.8 years (SD 9.3); 68% were women and 90% had symptoms for over three months.
Radial ESWT used EMS-DolorClast Evo blue handpiece, 15-mm applicator, three sessions about one week apart, 2,000 impulses at 10 Hz and 1.5–3 bar, focused on maximal lateral-epicondyle tenderness. Heavy-slow resistance group received a 12-week home program of 36 sessions, wrist flexion/extension and forearm pronation/supination with dumbbell, three sets, 4-s concentric/4-s eccentric, three times weekly; load was as heavy as possible for prescribed reps. All groups received written/oral information and advice; the advice-only group had one individual session up to 45 minutes.
Information and advice alone was the comparison group. The trial was designed to test recruitment, adherence, acceptability, retention and data completeness; it was not powered or designed for treatment-effect comparisons. The advice-only group could cross over after the 3-month follow-up.
Feasibility endpoints included recruitment, appointment attendance, intervention compliance, acceptability/comprehensibility, retention and data completeness. Secondary outcomes included PRTEE, Quick-DASH, EQ-5D-5L, pain-free grip strength, pain on gripping, NRS pain now and global rating of change. Outcomes were collected at baseline, 3 months and (questionnaires) 6 months.
Recruitment was 3.37 participants/month; 69/89 screened patients (78%) were eligible and 60/65 eligible patients (92%) accepted randomization. ESWT attendance was 60/60 sessions (100%); training participants completed median 26 of 36 sessions (range 6–35), with 6/19 (32%) reaching ≥30 sessions. Retention was 58/60 (97%) at 3 months and 41/60 (68%) at 6 months, below the prespecified >75% threshold. At 3 months median NRS pain-now was 1 (IQR 1–4) ESWT, 2 (0–6) training and 2 (1–4) advice; PRTEE total mean scores were 18.1, 25.7 and 23.9, respectively. Authors caution these are descriptive feasibility data, not comparative efficacy results.
Five exercise-group participants reported increased pain during training as an adverse event; eight reported increased pain as a reason for non-compliance. Two ESWT participants reported increased pain lasting up to 12 hours. No serious event count is stated in the inspected report.
The authors note 6-month retention was low, the traffic-light amber cut-off was not prespecified, the exercise group had no mandatory supervision, there was no blinded assessor, and acceptability was reported directly to the treating physiotherapist. Health-economic questionnaire feasibility was not assessed. Patients recently treated with shockwave/exercise/other treatments were not excluded, which may influence symptom descriptions.
The study indicates ESWT sessions and recruitment were feasible, while 6-month retention and adherence to heavy-slow exercise need changes. As a feasibility trial, descriptive improvement in symptoms cannot establish ESWT benefit over advice or exercise.
The authors recommend a full-scale randomized trial of radial ESWT and information/advice including sham ESWT. It should address retention, supervision, adverse-event monitoring, participant blinding and health economics.
Read the original article.
Heavy slow resistance training, radial extracorporeal shock wave therapy or advice for patients with tennis elbow in the Norwegian secondary care: a randomised controlled feasibility trial.
Sveinall H, Brox JI, Engebretsen KB, Hoksrud AF, Røe C, Johnsen MB. · BMJ open · 2024
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →